As part of the implementation of measures to develop the pharmaceutical industry of Kazakhstan, the Ministry of Health continues to hold meetings with major players in the global pharmaceutical industry, during which they discuss their future for presence in the Kazakh pharmaceutical market and investment in the industry, writes the press service of the agency.
The result of all previous agreements and the result of close cooperation with the Chinese side was the working visit of the Kazakh delegation to China in August 2023.
Within the framework of the trip, the possibilities of promoting the domestic pharmaceutical industry in the direction of technology transfer and increasing investment attractiveness were considered, and the issue of the Chinese party's visit to the Republic of Kazakhstan was worked out.
Thus, within the framework of the counter visit of the Chinese delegation to Kazakhstan, on September 20, Astana hosted a Kazakh Chinese forum on strengthening coordination and business cooperation in the field of pharmaceuticals between the Republic of Kazakhstan and the People's Republic of China.
"Cooperation with global pharmaceutical corporations should be intensified. It is important to attract investors, to ensure transfer of technologies and the latest developments", - noted the Head of State in his Address to the people of Kazakhstan.
China is the most important economic partner of Kazakhstan, and the potential of this relationship allows to realize joint projects of breakthrough level, in particular the realization of projects in the field of pharmaceutical and medical industry, which became the main topic of the Round Table.
The People's Republic of China was represented by the Vice President of the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE), representatives of China Meheco Corporation, China Sinopharm International Corporation, Shanghai United Imaging Healthcare Co. Ltd., Qilu Pharmaceutical Co., Ltd., Chengdu Kanghong Pharmaceutical Group Co., Ltd., Beijing Yuanli Biotechnology Co., Ltd., Tellgen Corporation, Suzhou and Science & Technology Development Corp. and Xian Qin (Tianjin) Medical Technology Co., Ltd.
Kazakhstan was represented by the Committee for Medical and Pharmaceutical Control of the Ministry of Health of the Republic of Kazakhstan, the Unified Distributor SK-Pharmacia LLP, the National Center for Expertise of Medicines and Medical Devices, the National Holding "QazBioPharm", the National Company "Kazakh Invest", and the Association "PharmMedIndustry of Kazakhstan" (AFMI), as well as a number of major domestic manufacturers represented by Kelun-Kazpharm LLP, Karaganda Pharmaceutical Complex LLP, Scientific and Production Enterprise Antigen LLP, BO-NA LLP, Nur-Mai Pharmacy LLP and Kazakhstan Aselsan Engineering.
The representative of SK-Pharmacia, who presented a brief overview of the Kazakhstani pharmaceutical market and types of procurement procedures, spoke from the Ministry's side. According to the report of the international analytical company IQVIA, the value of the Kazakhstan pharmaceutical market for the first half of 2023 increased by 17.1%, compared to the same period last year. It is noted that the volume of the market for 2022 amounted to $ 1.5 billion, most half of which is the share of the Single Distributor.
At the same time, in dynamics since 2010, the volume of purchases in monetary terms increased by 9.6 times. There is an increase in the volume of savings in absolute terms by 3.7 times.
The Government of Kazakhstan places great emphasis on localization of production of innovative drugs to increase the added value of the product portfolio of our manufacturers, technological re-equipment of the industry and development of R&D centers for in-house developments, thereby increasing the scientific and human resources potential of the country's pharmaceutical industry.
In order to attract large players to the industry, BigPharma provides a tool for concluding long-term agreements with contract manufacturing customers for 10 years, which allows localizing the production of original drugs in the country.
Along with this, the Kazakh side presented the current procedures for registration and pricing of medicines and medical devices in the Republic of Kazakhstan, as well as voiced the prospects for improving the legislative framework in the pharmaceutical industry, aimed at the effective functioning of a single market for medicines and medical devices within the Eurasian Economic Space.
Participants of the Chinese side also made counter reports, who presented the main directions of their activities and possible prospects of cooperation with Kazakhstani producers.
Close cooperation with the southeastern neighbors will definitely give impetus to attracting foreign investment, introduction of best practices in the development of pharmaceutical industry and transfer of innovative technologies of the Celestial Empire to Kazakhstan.
Source: https://forbes.kz